Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90

被引:265
作者
Blagosklonny, MV
Toretsky, J
Bohen, S
Neckers, L
机构
[1] NCI,CLIN PHARMACOL BRANCH,NIH,BETHESDA,MD 20892
[2] NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892
关键词
mutated p53; geldanamycin; chaperone; conformational recognition;
D O I
10.1073/pnas.93.16.8379
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The p53 mutant, 143(ala), was translated in vitro in either rabbit reticulocyte lysate (RRL) or wheat germ extract (WGE). In RRL, p53-143(ala) protein of both mutant and wild-type conformation, as detected immunologically with conformation-specific antibodies, was translated. The chaperone protein HSP90, present in RRL, was found to coprecipitate only with the mutated conformation of p53. Geldanamycin, shown previously to bind to HSP90 and destabilize its association with other proteins, decreased the amount of immunologically detectable mutated p53 and increased the amount of detectable wild-type protein, without affecting the total translation of p53. When translated in WGE, known to contain functionally deficient HSP90, p53-143(ala) produced p53 protein, which was not recognized by a mutated conformation-specific antibody. In contrast, the synthesis of conformationally detectable wild-type p53 in this system was not compromised, Reconstitution of HSP90 function in WGE permitted synthesis of conformationally detectable mutated p53, and this was abrogated by geldanamycin. Finally, when p53-143(ala) was stably transfected into yeast engineered to be defective for HSP90 function, conformational recognition of mutated p53 was impaired. When stable transfectants of p53-143(ala) were prepared in yeast expressing wildtype HSP90, conformational recognition of mutated p53 was antagonized by macbecin I, a geldanamycin analog also known to bind HSP90. Taken together, these data demonstrate a role for HSP90 in the achievement and/or stabilization of the mutated conformation of p53-143(ala). Furthermore, we show that the mutated conformation of p53 can be pharmacologically antagonized by drugs targeting HSP90.
引用
收藏
页码:8379 / 8383
页数:5
相关论文
共 39 条
  • [1] ANTONSSON C, 1995, MOL CELL BIOL, V15, P756
  • [2] BARTEK J, 1990, ONCOGENE, V5, P893
  • [3] BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933
  • [4] HSP90 MUTANTS DISRUPT GLUCOCORTICOID RECEPTOR-LIGAND BINDING AND DESTABILIZE APORECEPTOR COMPLEXES
    BOHEN, SP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (49) : 29433 - 29438
  • [5] ISOLATION OF HSP90 MUTANTS BY SCREENING FOR DECREASED STEROID-RECEPTOR FUNCTION
    BOHEN, SP
    YAMAMOTO, KR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) : 11424 - 11428
  • [6] CARVER LA, 1994, J BIOL CHEM, V269, P30109
  • [7] GAIN OF FUNCTION MUTATIONS IN P53
    DITTMER, D
    PATI, S
    ZAMBETTI, G
    CHU, S
    TERESKY, AK
    MOORE, M
    FINLAY, C
    LEVINE, AJ
    [J]. NATURE GENETICS, 1993, 4 (01) : 42 - 46
  • [8] THE TUMOR-SUPPRESSOR P53
    DONEHOWER, LA
    BRADLEY, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1155 (02) : 181 - 205
  • [9] ACTIVATING MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE MUTANT FORM
    GANNON, JV
    GREAVES, R
    IGGO, R
    LANE, DP
    [J]. EMBO JOURNAL, 1990, 9 (05) : 1595 - 1602
  • [10] GREENBLATT MS, 1994, CANCER RES, V54, P4855